KR20180127625A - Composition for antiinflammation containing extract of soybean root - Google Patents
Composition for antiinflammation containing extract of soybean root Download PDFInfo
- Publication number
- KR20180127625A KR20180127625A KR1020180142685A KR20180142685A KR20180127625A KR 20180127625 A KR20180127625 A KR 20180127625A KR 1020180142685 A KR1020180142685 A KR 1020180142685A KR 20180142685 A KR20180142685 A KR 20180142685A KR 20180127625 A KR20180127625 A KR 20180127625A
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- soybean
- present
- root extract
- soybean root
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 169
- 244000068988 Glycine max Species 0.000 title claims abstract description 87
- 235000010469 Glycine max Nutrition 0.000 title claims abstract description 87
- 239000000284 extract Substances 0.000 title claims abstract description 75
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 11
- 150000003180 prostaglandins Chemical class 0.000 claims description 21
- 238000004519 manufacturing process Methods 0.000 claims description 17
- 239000004480 active ingredient Substances 0.000 claims description 16
- 244000046052 Phaseolus vulgaris Species 0.000 claims description 15
- 239000002537 cosmetic Substances 0.000 claims description 14
- 235000010627 Phaseolus vulgaris Nutrition 0.000 claims description 12
- 102000015696 Interleukins Human genes 0.000 claims description 10
- 108010063738 Interleukins Proteins 0.000 claims description 10
- 229940094443 oxytocics prostaglandins Drugs 0.000 claims description 7
- 235000013402 health food Nutrition 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 4
- 235000006089 Phaseolus angularis Nutrition 0.000 claims description 4
- 240000007098 Vigna angularis Species 0.000 claims description 4
- 241001107116 Castanospermum australe Species 0.000 claims description 2
- 241000266501 Ormosia ormondii Species 0.000 claims description 2
- 240000008301 Rhynchosia minima Species 0.000 claims description 2
- 240000006677 Vicia faba Species 0.000 claims description 2
- 235000010749 Vicia faba Nutrition 0.000 claims description 2
- 235000002096 Vicia faba var. equina Nutrition 0.000 claims description 2
- 235000010711 Vigna angularis Nutrition 0.000 claims description 2
- 240000001417 Vigna umbellata Species 0.000 claims description 2
- 235000011453 Vigna umbellata Nutrition 0.000 claims description 2
- 235000021279 black bean Nutrition 0.000 claims description 2
- 244000013123 dwarf bean Species 0.000 claims description 2
- 235000005489 dwarf bean Nutrition 0.000 claims description 2
- 229940047122 interleukins Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 40
- 235000020712 soy bean extract Nutrition 0.000 abstract description 20
- 230000002401 inhibitory effect Effects 0.000 abstract description 16
- 206010061218 Inflammation Diseases 0.000 abstract description 14
- 239000011148 porous material Substances 0.000 abstract description 14
- 230000003266 anti-allergic effect Effects 0.000 abstract description 12
- 230000003020 moisturizing effect Effects 0.000 abstract description 12
- 239000000126 substance Substances 0.000 abstract description 11
- 230000004054 inflammatory process Effects 0.000 abstract description 9
- 210000002510 keratinocyte Anatomy 0.000 abstract description 7
- 230000015572 biosynthetic process Effects 0.000 abstract description 6
- 206010020751 Hypersensitivity Diseases 0.000 abstract description 5
- 230000007815 allergy Effects 0.000 abstract description 5
- 230000004069 differentiation Effects 0.000 abstract description 5
- 206010012438 Dermatitis atopic Diseases 0.000 abstract description 4
- 201000008937 atopic dermatitis Diseases 0.000 abstract description 4
- 208000024891 symptom Diseases 0.000 abstract description 4
- 208000026935 allergic disease Diseases 0.000 abstract description 3
- 201000010099 disease Diseases 0.000 abstract description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 2
- 230000007794 irritation Effects 0.000 abstract description 2
- 230000001737 promoting effect Effects 0.000 abstract description 2
- 206010048218 Xeroderma Diseases 0.000 abstract 1
- 230000003115 biocidal effect Effects 0.000 abstract 1
- 230000008602 contraction Effects 0.000 abstract 1
- 206010021198 ichthyosis Diseases 0.000 abstract 1
- 238000009472 formulation Methods 0.000 description 54
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 28
- 210000003491 skin Anatomy 0.000 description 26
- 230000000052 comparative effect Effects 0.000 description 24
- 238000012360 testing method Methods 0.000 description 15
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 14
- 239000004615 ingredient Substances 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 241000894006 Bacteria Species 0.000 description 12
- 208000002874 Acne Vulgaris Diseases 0.000 description 11
- 206010003645 Atopy Diseases 0.000 description 11
- 206010000496 acne Diseases 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- 239000003755 preservative agent Substances 0.000 description 10
- 239000008213 purified water Substances 0.000 description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 108010035532 Collagen Proteins 0.000 description 8
- 102000008186 Collagen Human genes 0.000 description 8
- 230000000844 anti-bacterial effect Effects 0.000 description 8
- -1 blockers Substances 0.000 description 8
- 229920001436 collagen Polymers 0.000 description 8
- 238000013329 compounding Methods 0.000 description 8
- 239000003205 fragrance Substances 0.000 description 8
- 239000008187 granular material Substances 0.000 description 8
- 230000002335 preservative effect Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 7
- 102000004890 Interleukin-8 Human genes 0.000 description 7
- 108090001007 Interleukin-8 Proteins 0.000 description 7
- 230000000845 anti-microbial effect Effects 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 239000006071 cream Substances 0.000 description 7
- 235000011187 glycerol Nutrition 0.000 description 7
- 229940096397 interleukin-8 Drugs 0.000 description 7
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 7
- 239000006210 lotion Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000004040 coloring Methods 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 230000003834 intracellular effect Effects 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 6
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 5
- NTQVODZUQIATFS-WAUHAFJUSA-N (2s)-2-[[(2s)-6-amino-2-[[2-[[(2s,3s)-2-[[(2s)-2-[[(2s)-2-amino-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-methylpentanoyl]amino]acetyl]amino]hexanoyl]amino]-3-methylbutanoic acid Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O NTQVODZUQIATFS-WAUHAFJUSA-N 0.000 description 5
- 102100037132 Proteinase-activated receptor 2 Human genes 0.000 description 5
- 101710121435 Proteinase-activated receptor 2 Proteins 0.000 description 5
- 229920002125 Sokalan® Polymers 0.000 description 5
- 108090000631 Trypsin Proteins 0.000 description 5
- 102000004142 Trypsin Human genes 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 5
- 239000012588 trypsin Substances 0.000 description 5
- 229940088594 vitamin Drugs 0.000 description 5
- 229930003231 vitamin Natural products 0.000 description 5
- 235000013343 vitamin Nutrition 0.000 description 5
- 239000011782 vitamin Substances 0.000 description 5
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 4
- 229920002498 Beta-glucan Polymers 0.000 description 4
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 4
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 4
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 4
- 229910001424 calcium ion Inorganic materials 0.000 description 4
- 229960003276 erythromycin Drugs 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 229930182478 glucoside Natural products 0.000 description 4
- 150000008131 glucosides Chemical class 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 229940057995 liquid paraffin Drugs 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 108010003179 seryl-leucyl-isoleucyl-glycyl-lysyl-valine Proteins 0.000 description 4
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 3
- 241000186427 Cutibacterium acnes Species 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 239000012981 Hank's balanced salt solution Substances 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 235000002789 Panax ginseng Nutrition 0.000 description 3
- 229920001214 Polysorbate 60 Polymers 0.000 description 3
- 229960001138 acetylsalicylic acid Drugs 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 229960001631 carbomer Drugs 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000036570 collagen biosynthesis Effects 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000004941 influx Effects 0.000 description 3
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 3
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 3
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 3
- 229940113124 polysorbate 60 Drugs 0.000 description 3
- 229940055019 propionibacterium acne Drugs 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 229940032094 squalane Drugs 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 108010013639 Peptidoglycan Proteins 0.000 description 2
- 108010050808 Procollagen Proteins 0.000 description 2
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 2
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 239000004902 Softening Agent Substances 0.000 description 2
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000003899 bactericide agent Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 229940081733 cetearyl alcohol Drugs 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 229960000735 docosanol Drugs 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 230000037336 dry skin Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- GSGDTSDELPUTKU-UHFFFAOYSA-N nonoxybenzene Chemical compound CCCCCCCCCOC1=CC=CC=C1 GSGDTSDELPUTKU-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 210000002374 sebum Anatomy 0.000 description 2
- 230000008591 skin barrier function Effects 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 229950011392 sorbitan stearate Drugs 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- SGPMJRPYYIJZPC-JYAZKYGWSA-N (2s,3s)-2-[[(2s)-2-[[(2s)-2-amino-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-n-[2-[[(2s)-1-[[(2s)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-2-oxoethyl]-3-methylpentanamide Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(C)C)C(N)=O SGPMJRPYYIJZPC-JYAZKYGWSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 108010063157 2-furoyl-LIGRLO-amide Proteins 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- DHFUFHYLYSCIJY-WSGIOKLISA-N CCCCCCCCCCCCCCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O Chemical compound CCCCCCCCCCCCCCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O DHFUFHYLYSCIJY-WSGIOKLISA-N 0.000 description 1
- 241001519020 Cassia brewsteri Species 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 240000005250 Chrysanthemum indicum Species 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 239000006137 Luria-Bertani broth Substances 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 244000088415 Raphanus sativus Species 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- QOMNQGZXFYNBNG-UHFFFAOYSA-N acetyloxymethyl 2-[2-[2-[5-[3-(acetyloxymethoxy)-2,7-difluoro-6-oxoxanthen-9-yl]-2-[bis[2-(acetyloxymethoxy)-2-oxoethyl]amino]phenoxy]ethoxy]-n-[2-(acetyloxymethoxy)-2-oxoethyl]-4-methylanilino]acetate Chemical compound CC(=O)OCOC(=O)CN(CC(=O)OCOC(C)=O)C1=CC=C(C)C=C1OCCOC1=CC(C2=C3C=C(F)C(=O)C=C3OC3=CC(OCOC(C)=O)=C(F)C=C32)=CC=C1N(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O QOMNQGZXFYNBNG-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 230000037319 collagen production Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000001023 inorganic pigment Substances 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 230000021995 interleukin-8 production Effects 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000012035 limiting reagent Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- OAQWWRSICWQQSE-UHFFFAOYSA-N octan-2-yl 16-methylheptadecanoate Chemical compound CCCCCCC(C)OC(=O)CCCCCCCCCCCCCCC(C)C OAQWWRSICWQQSE-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000012860 organic pigment Substances 0.000 description 1
- 235000019449 other food additives Nutrition 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940100460 peg-100 stearate Drugs 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
- 229960003081 probenecid Drugs 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000037384 skin absorption Effects 0.000 description 1
- 231100000274 skin absorption Toxicity 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 229940080352 sodium stearoyl lactylate Drugs 0.000 description 1
- ODFAPIRLUPAQCQ-UHFFFAOYSA-M sodium stearoyl lactylate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC(=O)OC(C)C(=O)OC(C)C([O-])=O ODFAPIRLUPAQCQ-UHFFFAOYSA-M 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 239000006097 ultraviolet radiation absorber Substances 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Birds (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 콩뿌리 추출물을 포함하는 항염증용, 항알러지용, 아토피 치료 또는 개선용, 보습용, 항균용 또는 모공 축소용 조성물에 관한 것이다. The present invention relates to an anti-inflammatory, anti-allergic, atopic treatment or remedy, moisturizing, antibacterial or pore-reducing composition containing soybean root extract.
인간의 피부는 인체의 일차 방어막으로서 온도 및 습도의 변화, 자외선, 공해물질과 같은 외부 환경의 자극으로부터 체내의 기관을 보호해 주는 기능을 하며, 나이가 들어감에 따라 여러 가지 내적, 외적 요인에 의해 변화를 겪는다. 즉, 내적으로는 신진대사를 조절하는 각종 호르몬의 분비가 감소하고, 면역 세포의 기능과 세포들의 활성이 저하되어 생체에 필요한 면역 단백질 및 생체 구성 단백질들의 생합성이 줄어들게 되며, 외적으로는 오존층 파괴로 인하여 태양 광선 중 지표에 도달하는 자외선의 함량이 증가하고 환경 오염이 더욱 심화됨에 따라 자유 라디칼 및 활성 유해 산소 등이 증가함으로써, 피부의 두께가 감소하고, 주름이 증가하며, 탄력이 감소될 뿐 아니라 피부 혈색도 칙칙해지고, 피부 트러블이 자주 발생하며, 기미와 주근깨 및 검버섯 또한 증가하는 등 여러 가지 변화를 일으키게 된다.Human skin is the primary protective membrane of the human body. It functions to protect the internal organs from external environmental stimuli such as changes in temperature and humidity, ultraviolet rays, and pollutants. Depending on various internal and external factors, It undergoes change. In other words, internally, secretion of various hormones that regulate metabolism is reduced, the function of immune cells and the activity of cells are lowered, and the biosynthesis of immune proteins and biocompatible proteins necessary for the living body is reduced, and ozone layer destruction As the content of ultraviolet rays reaching the surface of the sunlight increases and environmental pollution is further intensified, free radicals and active noxious oxygen are increased, so that the thickness of the skin decreases, the wrinkles increase, the elasticity decreases Skin color is grayish, skin troubles occur frequently, and spots, freckles and black blots also increase.
이러한 피부 내적 및 외적 요인에 의한 피부 상태의 변화를 방지하고, 건강한 피부 상태를 유지하기 위해서 기존에 알려진 각종 동물, 식물, 미생물 등으로부터 얻은 생리 활성 물질들을 화장품에 부가하여 사용함으로써 피부 상태를 개선시키기 위한 노력이 있어 왔다.In order to prevent the change of the skin condition due to the intrinsic and extrinsic factors, and to maintain a healthy skin condition, physiologically active substances obtained from various known animals, plants, microorganisms and the like are added to cosmetics to improve the skin condition There has been effort for.
이에 본 발명자들은 콩뿌리 추출물이 항염, 항알러지 효과뿐만 아니라 아토피 증상의 개선 효과도 제공할 수 있으며, 피부 보습 기능 효과 등의 피부 상태 개선 효과를 제공할 수 있음을 확인하고 본 발명을 완성하게 되었다.Accordingly, the inventors of the present invention have confirmed that soybean root extract can provide an anti-inflammatory and anti-allergic effect as well as an effect of improving atopic symptoms and can provide a skin condition improving effect such as a skin moisturizing function effect, thereby completing the present invention .
본 발명의 목적은 항염증용, 항알러지용, 아토피 치료 또는 개선용 또는 보습용으로 이용할 수 있는 천연 추출물을 포함하는 조성물을 제공하는 데 있다. It is an object of the present invention to provide a composition comprising a natural extract which can be used for anti-inflammation, anti-allergy, atopic treatment or improvement or moisturizing.
상기 목적을 달성하기 위하여, 본 발명은 콩뿌리 추출물을 유효성분으로 포함하는 항염증용 조성물을 제공한다.In order to achieve the above object, the present invention provides an anti-inflammatory composition comprising soybean root extract as an active ingredient.
본 발명은 또한 콩뿌리 추출물을 유효성분으로 포함하는 항알러지용 조성물을 제공하고, 콩뿌리 추출물을 유효성분으로 포함하는 아토피 치료 또는 개선용 조성물 및 콩뿌리 추출물을 유효성분으로 포함하는 보습용 조성물을 제공한다. The present invention also provides an antiallergic composition comprising soybean root extract as an active ingredient, and a composition for treating or improving atopy comprising soybean root extract as an active ingredient and a moisturizing composition comprising soybean root extract as an active ingredient to provide.
본 발명의 조성물은 염증의 원인 물질의 생성을 저해 또는 억제시켜 염증을 치료 또는 완화시킬 수 있는 항염증 효과를 가지고, 알러지를 치료 또는 완화시킬 수 있어서 유용하다. 또한 본 발명의 조성물은 아토피를 치료하거나 개선시킬 수 있고, 각질형성세포에서 분화를 촉진하여 보습 효과를 가지므로, 피부 건조증과 관련된 질환의 치료 또는 증상의 완화에 유용하며, 피부 가려움을 완화시킬 수 있다. 특히 본 발명의 조성물은 항염증능, 항알러지능, 아토피 치료 또는 개선능 또는 보습능에 있어서 콩 추출물보다 더 우수한 효과를 보인다. 본 발명의 조성물은 또한 천연물로부터 얻어지는 자연 유래의 추출물을 포함하여 생물체에 자극이 거의 없다. The composition of the present invention has an anti-inflammatory effect that can inhibit or inhibit the production of a causative substance of inflammation to treat or alleviate inflammation, and is useful for treating or alleviating allergy. In addition, the composition of the present invention can treat or ameliorate atopy, and promotes differentiation in keratinocytes to have a moisturizing effect. Therefore, it is useful for treatment of a disease associated with dry skin or to alleviate symptoms, have. In particular, the composition of the present invention exhibits more excellent effects than the soybean extract in anti-inflammatory, anti-allergic, atopic treatment or improving or moisturizing ability. The composition of the present invention is also free from irritation to organisms including natural extracts obtained from natural products.
본 명세서에서 '콩'은 그 종류에 제한이 없다. 본 발명의 일 관점인 조성물에 있어서, 구체적으로, 본 명세서의 콩은 서리태, 서목태, 흑태, 청태, 황태, 울타리콩, 강낭콩, 얼룩강낭콩, 적두, 거두, 콩나물콩 및 대두로 구성된 군으로부터 선택되는 어느 하나 이상을 포함할 수 있지만 이에 제한되는 것은 아니다. In this specification, the term 'bean' is not limited. In a composition according to one aspect of the present invention, the soybean of the present specification is selected from the group consisting of Seed Rice, Seomotei, Black Rice, Chungtae, Chrysanthemum, Fence, Soybean, Kidney Bean, But is not limited thereto.
본 명세서에서 '콩뿌리'는 콩나무의 뿌리 부분을 의미한다. In this specification, 'soybean root' means the root part of the bean tree.
본 명세서에서 '콩뿌리 추출물'은 추출과정에 있어서 예를 들면, 세척하고 건조시킨 콩뿌리 또는 이를 세말화한 콩뿌리 가루를 물 또는 유기용매에 넣고 추출하여 침적시킨 후 여과포 여과와 원심분리를 통해 잔사와 여액을 분리하고, 분리된 여액을 감압 농축하여 콩뿌리 추출물을 얻을 수 있다. 본 발명에 사용 가능한 유기용매는 에탄올, 메탄올, 부탄올, 에테르, 에틸아세테이트, 클로로포름 또는 이들 유기용매와 물의 혼합용매에서 선택될 수 있으며, 원료의 안전성을 고려할 때 바람직하게는 물 또는 30~70% 농도의 에탄올을 사용한다. 상기에서 용매를 이용하여 추출물을 얻은 이후 당업계에 알려진 통상적인 방법으로 상온에서 냉침, 가열 및 여과하여 액상물을 얻을 수 있으며, 또는 추가로 용매를 증발, 분무 건조 또는 동결 건조할 수 있으나, 이에 제한되는 것은 아니며, 당업계에서 일반적으로 사용되는 방법이라면 제한없이 사용하여 얻어질 수 있다.In the present invention, the 'soybean root extract' is extracted by, for example, washing and drying the soybean root or the soybean root powder in which the soybean root is washed with water or an organic solvent, and then extracting it by filtration and centrifugation The residue and the filtrate are separated, and the separated filtrate is concentrated under reduced pressure to obtain a soybean root extract. The organic solvent usable in the present invention may be selected from ethanol, methanol, butanol, ether, ethyl acetate, chloroform or a mixed solvent of these organic solvents and water. In view of the safety of raw materials, Of ethanol is used. After obtaining the extract by using the solvent, a liquid substance can be obtained by freezing, heating and filtering at room temperature by a conventional method known in the art. Alternatively, the solvent can be evaporated, spray dried or lyophilized But the present invention is not limited thereto, and any method generally used in the art can be used without limitation.
본 발명은 일 관점에서 콩뿌리 추출물을 유효성분으로 포함하는 항염증용 조성물에 관한 것이다. 본 발명의 일 관점인 상기 조성물은 피부 자극을 완화시키고, 염증을 완화시킬 수 있어서, 항염증용으로 사용할 수 있다. 구체적으로, 본 발명의 조성물은 프로스타글란딘 또는 인터루킨의 발현을 억제 또는 저해시키거나 또는 프로스타글란딘 또는 인터루킨의 활성을 억제 또는 저해시킴에 따라 항알러지 효과를 가져올 수 있다. The present invention relates to an antiinflammatory composition comprising soybean root extract as an active ingredient from an aspect. The composition, which is an aspect of the present invention, can alleviate skin irritation and alleviate inflammation, and thus can be used for anti-inflammation. Specifically, the composition of the present invention may have an anti-allergic effect by inhibiting or inhibiting the expression of prostaglandin or interleukin, or by inhibiting or inhibiting the activity of prostaglandin or interleukin.
본 발명은 일 관점에서 콩뿌리 추출물을 유효성분으로 포함하는 항알러지용 조성물에 관한 것이다. 본 발명의 일 관점인 상기 조성물은 알러지를 완화시키거나 또는 알러지의 원인이 되는 체내의 기작을 저해시켜서 알러지를 치료하거나 또는 완화시킬 수 있다. 구체적으로, 본 발명의 조성물은 프로스타글란딘 또는 인터루킨의 발현을 억제 또는 저해시키거나 또는 프로스타글란딘 또는 인터루킨의 활성을 억제 또는 저해시킴에 따라 항알러지 효과를 가져올 수 있다.The present invention relates to an antiallergic composition comprising soybean root extract as an active ingredient from an aspect. In one aspect of the present invention, the composition can treat or alleviate allergy by alleviating allergies or by inhibiting mechanisms in the body that cause allergies. Specifically, the composition of the present invention may have an anti-allergic effect by inhibiting or inhibiting the expression of prostaglandin or interleukin, or by inhibiting or inhibiting the activity of prostaglandin or interleukin.
본 발명은 일 관점에서 콩뿌리 추출물을 유효성분으로 포함하는 아토피 치료 또는 개선용 조성물에 관한 것이다. 본 발명의 일 관점인 상기 조성물은 항염증 및 항알러지 효과를 가질 뿐 아니라, 피부 장벽 기능을 강화시키고 피부 각질형성세포의 분화를 유도시킬 수 있어서, 피부 보호막의 이상 등이 원인이 되어 피부 건조증을 보이는 아토피의 치료 또는 아토피 증상의 완화를 위하여 사용할 수 있다. In one aspect, the present invention relates to a composition for treating or improving atopy comprising soybean root extract as an active ingredient. The composition, which is an aspect of the present invention, not only has anti-inflammatory and anti-allergic effects, but also can enhance skin barrier function and induce differentiation of dermal keratinocytes, Can be used for the treatment of visible atopy or for alleviation of atopic symptoms.
본 발명은 일 관점에서 콩뿌리 추출물을 유효성분으로 포함하는 보습용 조성물에 관한 것이다. 본 발명의 일 관점인 상기 조성물은 피부 장벽 기능을 강화시키고 피부 각질형성세포의 분화를 유도시켜서 피부의 수분을 증가킴에 따라 촉촉한 피부로 만들 수 있다. 따라서 본 발명의 일 관점인 상기 조성물은 표피 분화의 불완전함으로 생기는 피부건조증, 아토피 피부염, 접촉성 피부염 또는 건선 등을 예방 또는 개선하는 조성물로 유용하게 사용될 수 있다.In one aspect, the present invention relates to a moisturizing composition comprising soybean root extract as an active ingredient. The composition, which is an aspect of the present invention, can enhance the skin barrier function and induce the differentiation of dermal keratinocytes, thereby increasing the moisture content of the skin and making the skin moist. Therefore, the composition as one aspect of the present invention can be usefully used as a composition for preventing or improving dry skin, atopic dermatitis, contact dermatitis, psoriasis, or the like caused by incomplete epidermal differentiation.
본 발명은 일 관점에서 콩뿌리 추출물을 유효성분으로 포함하는 항균용 조성물에 관한 것이다. 본 발명의 일 관점인 상기 조성물은 구체적으로, 여드름균에 대하여 우수한 항균력을 보인다. 그러므로 상기 조성물은 여드름의 치료 및 완화에 있어서 효과적으로 사용가능하다. The present invention relates to an antimicrobial composition comprising soybean root extract as an active ingredient from an aspect. The composition, which is one aspect of the present invention, specifically shows excellent antibacterial activity against acne bacteria. Therefore, the composition can be effectively used in the treatment and alleviation of acne.
본 발명은 다른 일 관점에서 콩뿌리 추출물을 유효성분으로 포함하는 모공 축소용 조성물에 관한 것이다. 본 발명의 일 관점인 상기 조성물은 구체적으로, 콜라겐의 생합성을 증가시켜, 모공의 크기를 축소시킬 수 있다. The present invention relates to a composition for shrinking pores comprising soybean root extract as an active ingredient from another aspect. The composition as one aspect of the present invention specifically can increase the biosynthesis of collagen and reduce the size of pores.
본 발명의 조성물은 각종 이유로 발생하는 피부 트러블 또는 피부 질환의 완화, 상태의 개선을 의미하거나 또는 피부 트러블 또는 피부 질환을 유발하는 각종 이유를 제거하거나 저해할 수 있고, 피부 외적인 상태 또는 이를 유발하는 피부 내적인 상태를 개선할 수 있어서 피부 상태를 개선시키는 데 유용하다. The composition of the present invention means to alleviate the skin troubles or skin diseases caused by various reasons, to improve the condition, or to remove or inhibit various reasons causing skin troubles or skin diseases, It can improve the internal condition and is useful for improving skin condition.
본 발명의 조성물은 또한 모공 축소, 피지 조절 및 피부 트러블 개선용 조성물로서 사용될 수 있으며, 이는 피부에 적용 시 과잉으로 분비되는 피지를 억제하고, 활성 산소 제거와 콜라겐 합성을 촉진함으로써 모공을 축소시키며, 염증 인자의 발현 감소로 피부 트러블을 억제하는 효과가 탁월하다.The composition of the present invention can also be used as a composition for reducing pores, controlling sebum, and improving skin troubles. It reduces sebum secreted by the skin when applied to the skin, reduces active oxygen and promotes collagen synthesis, The reduction of the expression of inflammatory factors leads to an excellent effect of suppressing skin troubles.
본 발명의 일 관점인 조성물에 있어서, 상기 조성물은 조성물 총 중량에 대하여 0.001 내지 10 중량%의 콩뿌리 추출물을 포함할 수 있다. In one aspect of the present invention, the composition may comprise from 0.001 to 10% by weight of soybean root extract, based on the total weight of the composition.
조성물 총 중량에 대하여 콩뿌리 추출물의 함량이 0.001중량% 미만이면 항염, 항알러지, 아토피 등의 피부 트러블 개선, 피부 보습 효과가 미미하고, 10중량%를 초과하면 함유량 증가에 따른 뚜렷한 효과의 증가가 나타나지 않기 때문이다. 상기와 같은 관점에 있어서, 본 발명의 조성물은 조성물 총 중량에 대하여, 0.005~9.5중량%, 0.01~9중량%, 0.03~8.5중량%, 0.05~8중량%, 0.07~7.5중량%, 0.09~7중량%, 0.1~6.5중량%, 0.3~6중량%, 0.5~5.5중량% 또는 0.7~5중량%의 콩뿌리 추출물을 포함할 수 있다.If the content of soybean root extract is less than 0.001% by weight based on the total weight of the composition, improvement of skin troubles such as anti-inflammation, anti-allergy and atopy and skin moisturizing effect are insignificant, and if it exceeds 10% by weight, Because it does not appear. In view of the above, the composition of the present invention is used in an amount of 0.005 to 9.5% by weight, 0.01 to 9% by weight, 0.03 to 8.5% by weight, 0.05 to 8% by weight, 0.07 to 7.5% by weight, The bean root extract may contain 7% by weight, 0.1 to 6.5% by weight, 0.3 to 6% by weight, 0.5 to 5.5% by weight or 0.7 to 5% by weight.
본 발명의 일 관점인 조성물에 있어서, 상기 콩은 서리태 (Seoritae, Glycin max MERR), 서목태 (Seomoktae, Rhynchosia Nolubilis), 흑태 (Black soybean, Glycine max(L.) Merr.), 청태 (blue bean, Glycime max MERR ), 황태 (yellow bean, Glycime max MERR), 울타리콩 (field bean, Vicia faba), 강낭콩 (kidney bean, Phaseolus vulgaris), 얼룩강낭콩 (pinto bean, Phaseolus vulgaris L.), 적두 (small red bean, Vigna angularis), 거두 (small black bean, Phaseolus angularis W.F. WIGHT. ), 콩나물콩 (sprouting bean, Glycine max (L.) Merr.) 및 대두 (soybean, Glycine max)로 구성된 군으로부터 선택되는 어느 하나 이상을 포함한다. In one aspect of the present invention, the soybean is selected from the group consisting of Seoritae, Glycin max MERR, Seomoktae, Rhynchosia Nolubilis , Black soybean, Glycine max (L.) Merr., Blue bean, Glycime max MERR), yellow bean ( Glycime max MERR), field bean ( Vicia faba ), kidney bean ( Phaseolus vulgaris ), pinto bean ( Phaseolus vulgaris L.), small red bean, Vigna angularis , small black bean, Phaseolus angularis WF WIGHT, sprouting bean, Glycine max (L.) Merr. and soybean ( Glycine max ) Or more.
본 발명의 일 관점인 조성물에 있어서, 상기 조성물은 프로스타글란딘의 생성을 억제 또는 저해시킬 수 있다. 본 발명의 일 관점인 상기 조성물은 프로스타글란딘 자체의 생성을 억제 또는 저해시킬 수 있거나 또는 프로스타글란딘의 활성을 억제 또는 저해시킬 수 있다. 본 발명의 일 관점인 상기 조성물은 또한 프로스타글란딘을 생성시키는 전단계 (up-stream)의 효소 또는 단백질의 활성을 억제 또는 저해시킬 수 있다. In one aspect of the present invention, the composition may inhibit or inhibit the production of prostaglandins. In one aspect of the present invention, the composition can inhibit or inhibit the production of prostaglandin itself, or inhibit or inhibit the activity of prostaglandins. The composition, which is an aspect of the present invention, can also inhibit or inhibit the activity of an up-stream enzyme or protein that produces prostaglandins.
본 발명의 일 관점인 조성물에 있어서, 상기 조성물은 인터루킨의 생성을 억제 또는 저해시킬 수 있다. 본 발명의 일 관점인 상기 조성물은 인터루킨 자체의 생성을 억제 또는 저해시킬 수 있거나 또는 인터루킨의 활성을 억제 또는 저해시킬 수 있다. 본 발명의 일 관점인 상기 조성물은 또한 인터루킨을 생성시키는 전단계 (up-stream)의 효소 또는 단백질의 활성을 억제 또는 저해시킬 수 있다. 구체적으로 상기 인터루킨은 인터루킨-6 또는 인터루킨-8을 포함할 수 있지만, 이에 제한되는 것은 아니다. In one aspect of the invention, the composition may inhibit or inhibit the production of interleukin. In one aspect of the invention, the composition may inhibit or inhibit the production of the interleukin itself or may inhibit or inhibit the activity of the interleukin. The composition, which is an aspect of the present invention, may also inhibit or inhibit the activity of an up-stream enzyme or protein that produces interleukin. Specifically, the interleukin may include interleukin-6 or interleukin-8, but is not limited thereto.
본 발명의 일 관점인 조성물에 있어서, 상기 균은 여드름균을 포함한다. In one aspect of the present invention, the bacterium comprises an acne bacterium.
본 발명의 일 관점인 조성물에 있어서, 상기 조성물은 콜라겐의 생합성을 촉진시킬 수 있다. 상기 조성물은 콜라겐 자체의 생합성을 촉진시키거나 또는 활성을 증가시킬 수 있으며, 또는 콜라겐을 생성시키는 전단계 (up-stream)의 효소 또는 단백질의 활성을 증가 또는 촉진시킬 수 있다.In a composition according to one aspect of the present invention, the composition may promote collagen biosynthesis. The composition may promote the biosynthesis of the collagen itself or may increase the activity, or may increase or promote the activity of an up-stream enzyme or protein that produces collagen.
본 발명의 일 관점인 조성물에 있어서, 상기 조성물은 화장료 조성물을 포함한다. In one aspect of the invention, the composition comprises a cosmetic composition.
본 발명에 따른 피부 외용제 조성물을 화장료의 형태로 제형화 할 경우, 유연화장수, 수렴화장수, 영양화장수, 아이 크림, 영양 크림, 마사지 크림, 클렌징 크림, 클렌징 폼, 클렌징 워터, 파우더, 에센스 또는 팩 등의 형태로 제형화 될 수 있으며, 그 제형이 특별히 한정되는 것은 아니다. 또한, 본 발명에 의한 조성물은 지방 물질, 유기용매, 용해제, 농축제, 겔화제, 연화제, 항산화제, 현탁화제, 안정화제, 발포제(foaming agent), 방향제, 계면활성제, 물, 이온형 또는 비이온형 유화제, 충전제, 금속이온봉쇄제, 킬레이트화제, 보존제, 비타민, 차단제, 습윤화제, 필수 오일, 염료, 안료, 친수성 또는 친유성 활성제, 지질 소낭 또는 화장품에 통상적으로 사용되는 임의의 다른 성분과 같은 화장품학 또는 피부과학 분야에서 통상적으로 사용되는 보조제를 함유할 수 있다. 상기 보조제는 화장품학 또는 피부과학 분야에서 일반적으로 사용되는 양으로 도입된다. 또한, 본 발명의 조성물은 피부 개선 효과를 증가시키기 위하여 피부 흡수 촉진 물질을 함유할 수 있다.When the composition for external application for skin according to the present invention is formulated in the form of a cosmetic composition, it may be formulated into a form of cosmetics such as a softening agent, a convergent lotion, a nutritional lotion, an eye cream, a nutrition cream, a massage cream, a cleansing cream, a cleansing foam, a cleansing water, And the formulations thereof are not particularly limited. In addition, the composition according to the present invention can also be used as a lubricant, an organic solvent, a solubilizer, a thickening agent, a gelling agent, a softening agent, an antioxidant, a suspending agent, a stabilizer, a foaming agent, a fragrance, The active ingredient may be combined with any other ingredients commonly used in cosmetics, such as ionic emulsifiers, fillers, sequestering agents, chelating agents, preservatives, vitamins, blockers, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic active agents, And may contain adjuvants commonly used in the same cosmetic or dermatological fields. Such adjuvants are introduced in amounts commonly used in the cosmetics or dermatological fields. In addition, the composition of the present invention may contain a skin absorption promoting substance to increase the skin improving effect.
본 발명에 따른 화장료 조성물은 상기한 물질 이외에 주 효과를 손상시키지 않는 범위 내에서, 바람직하게는 주 효과에 상승 효과를 줄 수 있는 다른 성분들을 포함할 수 있다. 또한 본 발명에 따른 화장료 조성물은 보습제, 에몰리언트제, 자외선 흡수제, 방부제, 살균제, 산화 방지제, pH 조정제, 유기 및 무기 안료, 향료, 냉감제 또는 제한제를 더 포함할 수 있다. 상기 성분의 배합량은 본 발명의 목적 및 효과를 손상시키지 않는 범위 내에서 당업자가 용이하게 선정 가능하며, 그 배합량은 조성물 전체 중량을 기준으로 0.01 내지 5 중량%, 구체적으로 0.01 내지 3 중량%일 수 있다.The cosmetic composition according to the present invention may contain, in addition to the above-mentioned substances, other ingredients which can give a synergistic effect to the main effect, so long as they do not impair the main effect. The cosmetic composition according to the present invention may further comprise a moisturizing agent, an emollient agent, an ultraviolet absorber, an antiseptic, a bactericide, an antioxidant, a pH adjuster, an organic and inorganic pigment, a fragrance, a cold agent or a limiting agent. The compounding amount of the above components can be easily selected by those skilled in the art within a range not to impair the objects and effects of the present invention. The amount thereof may be 0.01 to 5% by weight, specifically 0.01 to 3% by weight, have.
본 발명의 일 관점인 조성물에 있어서, 상기 조성물은 약학 조성물을 포함한다. In one aspect of the invention, the composition comprises a pharmaceutical composition.
본 발명에 따른 조성물을 의약품에 적용할 경우에는, 상기 조성물을 유효성분으로 하여 상용되는 무기 또는 유기의 담체를 가하여 고체, 반고체 또는 액상의 형태로 경구 투여제 혹은 비경구 투여제로 제제화 할 수 있다. When the composition according to the present invention is applied to medicines, it may be formulated into an oral or parenteral dosage form in the form of solid, semi-solid or liquid by adding an inorganic or organic carrier to the composition as an active ingredient.
상기 경구 투여를 위한 제재로서는 정제, 환제, 과립제, 캡슐제, 산제, 세립제, 분제, 유탁제, 시럽제, 펠렛제 등을 들 수 있다. 또한, 상기 비경구 투여를 위한 제재로는 주사제, 점적제, 연고, 로션, 스프레이, 현탁제, 유제, 좌제, 패치 등을 들 수 있다. 본 발명의 유효성분을 제제화하기 위해서는 상법에 따라서 실시하면 용이하게 제제화할 수 있으며 계면활성제, 부형제, 착색료, 향신료, 보존료, 안정제, 완충제, 현탁제, 기타 상용하는 보조제를 적당히 사용할 수 있다.Examples of the agent for oral administration include tablets, pills, granules, capsules, powders, fine granules, powders, emulsions, syrups and pellets. Examples of the parenteral administration agent include injections, drops, ointments, lotions, sprays, suspensions, emulsions, suppositories, and patches. In order to formulate the active ingredient of the present invention, it can be easily formulated according to the conventional method. Surfactants, excipients, coloring agents, spices, preservatives, stabilizers, buffering agents, suspending agents and other adjuvants can be suitably used.
본 발명에 따른 상기 약학 조성물은 경구, 비경구, 직장, 국소, 경피, 정맥 내, 근육 내, 복강 내, 피하 등으로 투여될 수 있다. The pharmaceutical composition according to the present invention may be administered orally, parenterally, rectally, topically, transdermally, intravenously, intramuscularly, intraperitoneally, subcutaneously and the like.
본 발명의 약학 조성물의 유효 성분은 투여 받을 대상의 연령, 성별, 체중, 병리 상태 및 그 심각도, 투여 경로 또는 처방자의 판단에 따라 달라질 것이다. 이러한 인자에 기초한 적용량 결정은 당업자의 수준 내에 있으며, 이의 1일 투여 용량은 예를 들어 0.1mg/kg/일 내지 100mg/kg/일, 보다 구체적으로는 5 mg/kg/일 내지 50 mg/kg/일이 될 수 있으나, 이에 제한되는 것은 아니다.The effective ingredients of the pharmaceutical composition of the present invention will vary depending on the age, sex, weight, pathological condition and severity of the subject to be treated, administration route or judgment of the prescriber. Determination of the amount of application based on these factors is within the level of ordinary skill in the art and its daily dose is, for example, from 0.1 mg / kg / day to 100 mg / kg / day, more specifically from 5 mg / kg / day to 50 mg / / Day, but is not limited thereto.
본 발명의 일 관점인 조성물에 있어서, 상기 조성물은 건강식품 조성물을 포함한다. In one aspect of the invention, the composition comprises a health food composition.
본 발명에 따른 조성물은 포함하는 다양한 형태의 식품 첨가제 또는 기능성 식품을 제공한다. 상기 조성물을 포함하는 발효유, 치즈, 요구르트, 주스, 생균제제, 정제, 과립제, 드링크제, 캐러멜, 다이어트바 등으로 제형화될 수 있고, 통상적인 차 잎 형태나 티백 및 건강보조식품 등으로 가공될 수 있으며, 그 외 다양한 식품 첨가제의 형태로 사용될 수 있다. The composition according to the present invention provides various types of food additives or functional foods containing them. The composition may be formulated into fermented milk, cheese, yogurt, juice, probiotics, tablets, granules, drinks, caramels, diet bars, and the like, and may be processed into ordinary tea leaves, tea bags, And can be used in the form of various other food additives.
일실시예에서 상기 조성물은, 본 발명이 목적으로 하는 주 효과를 손상시키지 않는 범위 내에서 주 효과에 상승 효과를 줄 수 있는 다른 성분 등을 함유할 수 있다. 예를 들어, 물성 개선을 위하여 향료, 색소, 살균제, 산화방지제, 방부제, 보습제, 점증제, 무기염류, 유화제 및 합성 고분자 물질 등의 첨가제를 더 포함할 수 있다. 그 외에도, 수용성 비타민, 유용성 비타민, 고분자 펩티드, 고분자 다당 및 해초 엑기스 등의 보조 성분을 더 포함할 수도 있다. 상기 성분들은 제형 또는 사용 목적에 따라서 당업자가 어려움 없이 적의 선정하여 배합할 수 있으며, 그 첨가량은 본 발명의 목적 및 효과를 손상시키지 않는 범위 내에서 선택될 수 있다. 예를 들어, 상기 성분들의 첨가량은, 조성물 전체 중량을 기준으로, 0.01~5 중량%, 보다 구체적으로는 0.01~3 중량% 범위일 수 있다.In one embodiment, the composition may contain other ingredients or the like that can give synergistic effects to the main effect within a range that does not impair the intended main effect of the present invention. For example, additives such as perfume, coloring agent, bactericide, antioxidant, preservative, moisturizing agent, thickening agent, inorganic salt, emulsifier and synthetic polymer substance may be further added for improvement of physical properties. In addition, it may further contain auxiliary components such as water-soluble vitamins, oil-soluble vitamins, polymer peptides, polymeric polysaccharides and seaweed extract. The above components may be mixed and selected without difficulty by those skilled in the art depending on the purpose of formulation or use, and the amount thereof may be selected within a range that does not impair the objects and effects of the present invention. For example, the addition amount of the above components may be in the range of 0.01 to 5% by weight, more specifically 0.01 to 3% by weight, based on the total weight of the composition.
본 발명에 따른 조성물의 제형은 용액, 유화물, 점성형 혼합물, 타블렛, 분말 등의 다양한 형태일 수 있으며, 이는 단순 음용, 주사 투여, 스프레이 방식 또는 스퀴즈 방식 등의 다양한 방법으로 투여될 수 있다.The composition according to the present invention may be in various forms such as a solution, an emulsion, a viscous mixture, a tablet, a powder, etc., and may be administered by various methods such as simple drinking, injection administration, spraying or squeezing.
이하, 실시예를 통하여 본 발명을 더욱 상세히 설명하고자 한다. 이들 실시예는 오로지 본 발명을 예시하기 위한 것으로, 본 발명의 범위가 이들 실시예에 의해 제한되는 것으로 해석되지 않는 것은 당업계에서 통상의 지식을 가진 자에게 있어서 자명할 것이다. Hereinafter, the present invention will be described in more detail with reference to Examples. It is to be understood by those skilled in the art that these embodiments are only for illustrating the present invention and that the scope of the present invention is not construed as being limited by these embodiments.
[제조예 1] 콩뿌리 추출물의 제조[Preparation Example 1] Preparation of soybean root extract
콩뿌리 1.5 kg을 믹서기로 분쇄한 뒤 80% 에탄올 수용액 7 ℓ를 넣고, 3회 환류 추출한 다음, 15℃에서 1일간 침적시켰다. 그 후, 여과포 여과와 원심분리를 통해 잔사와 여액을 분리하고, 분리된 여액을 감압 농축하여 콩뿌리 추출물 216 g을 얻었다.1.5 kg of soybean root was pulverized with a mixer, and 7 liters of 80% aqueous ethanol solution was added, refluxed for 3 times, and then immersed at 15 ° C for 1 day. Thereafter, the residue and the filtrate were separated by filtration through a filter cloth and centrifugation, and the separated filtrate was concentrated under reduced pressure to obtain 216 g of soybean root extract.
[비교예 1] 콩 추출물의 제조[Comparative Example 1] Production of soybean extract
콩 1.5 kg을 믹서기로 분쇄한 뒤 80% 에탄올 수용액 7 ℓ를 넣고, 3회 환류 추출한 다음, 15℃에서 1일간 침적시켰다. 그 후, 여과포 여과와 원심분리를 통해 잔사와 여액을 분리하고, 분리된 여액을 감압 농축하여 콩 추출물 252 g을 얻었다.1.5 kg of soybean was pulverized with a mixer, and 7 liters of 80% aqueous ethanol solution was added thereto, refluxed three times, and then immersed at 15 ° C for 1 day. Thereafter, the residue and the filtrate were separated by filtration through a filter cloth and centrifugation, and the separated filtrate was concentrated under reduced pressure to obtain 252 g of a soybean extract.
[시험예 1] 염증 개선 효과[Test Example 1] Inflammation improving effect
1. 프로스타글란딘의 생성 억제 효과1. Inhibitory effect of prostaglandins
항염증 효과를 프로스타글란딘의 생성 억제 효과로 평가하였다. 콩뿌리 추출물과 비교예 1의 콩 추출물을 이용하여 대식세포를 대상으로 효과를 측정하였다. 우선, 마우스의 복강에서 채취한 대식세포에 최종농도가 500uM이 되도록 아스피린을 첨가해 세포에 잔존하는 시클로옥시제나제(cyclooxygenase, COX) 활성을 비가역적으로 억제하였다. 그런 다음 상기 현탁액을 96웰의 세포 배양관의 각 웰에 100μl를 넣어 5% CO2와 37℃ 조건의 배양기에서 2시간 동안 배양하여 대식 세포를 용기 표면에 부착시켰다. 이어, 부착된 대식 세포를 PBS로 3회 세척한 후 이를 염증 개선 효과 시험에 사용하였다. 상기 배양된 대식세포 5x104 세포/ml에 LPS를 1%(w/v)로 함유하는 RPMI 배지를 첨가하여 12시간 동안 배양한 후 프로스타글란딘의 생성을 유발하고 콩뿌리 추출물을 100μl 처리하여 유리된 프로스타글란딘을 효소면역 분석법(ELISA)을 이용하여 정량하였다.The anti - inflammatory effect was evaluated by the inhibitory effect of prostaglandin production. The soybean root extract and the soybean extract of Comparative Example 1 were used to measure the effect on macrophages. First, aspirin was added to the macrophage collected from mouse peritoneum to a final concentration of 500 uM to irreversibly inhibit the cyclooxygenase (COX) activity remaining in the cells. Then, the suspension was added to each well of a 96-well cell culture tube in an amount of 100 μl, followed by culturing in an incubator of 5% CO 2 and 37 ° C for 2 hours to adhere macrophages to the surface of the container. Then, the adhered macrophages were washed three times with PBS and used for the inflammation improving effect test. RPMI medium containing 1% (w / v) LPS was added to the cultured macrophage 5x10 4 cells / ml and cultured for 12 hours to induce the production of prostaglandin. 100 μl of soybean root extract was added to the free prostaglandin Were quantitated using enzyme immunoassay (ELISA).
이때, 콩뿌리 추출물의 프로스타글란딘의 생성억제 활성은 LPS를 처리한 군과 처리하지 않은 군에서 각각 생성된 프로스타글란딘의 차이를 100%로 설정하고, LPS와 시료를 함께 처리하여 감소된 프로스타글란딘의 백분율을 통하여 대조군과 비교, 판정하였으며, 그 결과(프로스타글란딘의 생성억제 효과)를 하기 표 1에 나타내었다.At this time, the inhibitory activity on the production of prostaglandin of soybean root extract was determined by setting the difference of prostaglandins produced in the LPS-treated group and the untreated group to 100%, and by treating the LPS and the sample together to decrease the percentage of prostaglandin (Control effect of prostaglandin production) is shown in Table 1 below.
상기 표 1에서 보는 바와 같이, 실험결과 아스피린으로 처리한 대조군과 같이 콩뿌리 추출물을 처리한 경우에도 프로스타글란딘의 생성 억제 효과가 매우 높음을 알 수 있다. 또한 콩 추출물에 비하여 콩뿌리 추출물은 프로스타글란딘의 생성 억제 효과가 더 우수함을 알 수 있다. 이를 통해 본 발명의 콩뿌리 추출물은 우수한 염증 개선 효과를 제공할 수 있음을 알 수 있다. 또한, 콩뿌리 추출물은 피부 염증 인자인 프로스타글란딘의 발현을 억제하여 피부 트러블을 방지하고 개선시킬 수 있음을 알 수 있다. As shown in the above Table 1, the inhibition effect of prostaglandin production is very high even when the soybean root extract is treated as in the control group treated with aspirin. In addition, the soybean root extract has a better inhibitory effect on the production of prostaglandins than the soybean extracts. Thus, it can be seen that the soybean root extract of the present invention can provide an excellent inflammation improving effect. In addition, soybean root extract inhibits the expression of prostaglandin, which is a skin inflammation factor, to prevent and improve skin troubles.
2. IL-8 생성 억제 효과2. IL-8 production inhibitory effect
실험 하루 전 피부 각화상피세포(Normal human skin keratinocyte, NHEK, 입수처: Lonza)를 96웰(well) 플레이트에 5x104 세포/웰이 되도록 분주한 후 37℃, 5% CO2 인큐베이터(incubator)에서 24시간 동안 배양하였다. 24시간 후, PBS로 세포를 2회 씻어주고 무혈청 KBM(serum free keratinocyte basement media)으로 갈아주었다. 콩 추출물 50ppm과 각각의 웰에 콩뿌리 추출물을 하기 표 2의 농도별로 처리하여 30분간 반응시킨 후, PGSA(10㎍/㎖) 를 각각의 웰에 처리하였다. 여기서, PGSA(peptidoglycan from S. aureus)는 포도상구균에서 추출한 펩티도글리칸(peptidoglycan)으로서, 그람 양성(+) 균의 세포벽의 주요 구성 성분이고 박테리아의 세포막 성분들은 염증을 유발시키는 것으로 알려져 있으며, 특히 포도상구균의 경우 아토피 환자의 90% 정도가 이 균에 의한 2차 감염을 일으키는 것으로 보고되어 있다. 24시간 동안 37℃, 5% CO2 인큐베이터에서 배양한 후 배양액을 취하여 인터루킨-8(Interleukin-8, IL-8)에 대한 ELISA를 진행하였으며, 그 결과를 하기 표 2에 나타내었다. ELISA는 제조회사(BD science)의 실험 방법을 이용하였다.The day before the experiment, normal human skin keratinocyte (NHEK, available from Lonza) was dispensed into a 96 well plate at 5 × 10 4 cells / well and incubated at 37 ° C. in a 5% CO 2 incubator And cultured for 24 hours. Twenty-four hours later, the cells were washed twice with PBS and replaced with serum free keratinocyte basement media (KBM). 50 ppm of soybean extract and soybean root extract in each well were treated at the concentrations shown in the following Table 2 for 30 minutes and treated with PGSA (10 μg / ml) in each well. Here, peptidoglycan from S. aureus (PGSA ) is a peptidoglycan extracted from Staphylococcus aureus, which is a major constituent of the cell wall of Gram-positive (+) bacteria, and the cell membrane components of bacteria are known to cause inflammation, Especially in staphylococcus, about 90% of atopic patients are reported to cause secondary infection by this bacterium. After culturing in a 5% CO 2 incubator at 37 ° C for 24 hours, the culture was taken and ELISA for interleukin-8 (IL-8) was performed. The results are shown in Table 2 below. The ELISA used the experimental method of BD science.
상기 표 2에서 콩뿌리 추출물이 PGSA와 LPS에 의해 증가한 IL-8의 분비를 현저히 감소 및 억제시키는 것을 확인할 수 있었다. 또한 콩 추출물과 비교하여도 현저히 높은 IL-8 분비 억제 효과를 확인 할 수 있었다. 따라서, 본 발명의 피부 외용제 조성물은 PGSA 의해 증가한 IL-8의 분비를 현저히 감소시킴으로써 우수한 항염증 효과를 제공할 수 있음을 알 수 있다.In Table 2, it was confirmed that the soybean root extract significantly reduced and inhibited the secretion of IL-8 increased by PGSA and LPS. In addition, IL-8 secretion inhibition was remarkably higher than soybean extract. Accordingly, it can be seen that the composition for external application for skin of the present invention can provide a superior anti-inflammatory effect by significantly reducing the secretion of IL-8 increased by PGSA.
[시험예 2] 가려움 완화 평가[Test Example 2] Evaluation of itching relief
실험 하루 전 각질형성세포(세포주명: HaCaT 입수처: ATCC)를 96 웰(well) 플레이트에 4x104세포/웰이 되도록 분주한 후 37℃, 5% CO2 인큐베이터(incubator)에서 24시간 동안 배양하였다. 24시간 후, HBSS(Hanks’Balanced Salt solution) 버퍼로 96 웰 플레이트를 2회 워싱(washing)한 후, 반응 버퍼(2μM Fluo-4-AM, 20% pluronic acid, 2.5mM probenecid)를 세포에 넣어주었다. 37℃, 5% CO2 인큐베이터에서 30분, 상온에서 30분간 반응시킨 후, HBSS 버퍼로 2회 워싱 하고 하기 표 3과 같은 농도(%)의 콩뿌리 추출물로 세포를 처리하였다. The day before the experiment, keratinocytes (cell line name: HaCaT available from ATCC) were dispensed in a 96 well plate at 4x10 4 cells / well and cultured in a 5% CO 2 incubator at 37 ° C for 24 hours Respectively. After 24 hours, the 96-well plate was washed twice with HBSS (Hanks' Balanced Salt Solution) buffer, and the reaction buffer (2 μM Fluo-4-AM, 20% pluronic acid, 2.5 mM probenecid) gave. After incubation at 37 ° C in a 5% CO 2 incubator for 30 minutes and at room temperature for 30 minutes, the cells were treated with the soybean root extract of the concentration (%) shown in Table 3 below, washed twice with HBSS buffer.
10분간 반응시킨 후, 2U/ml 트립신(Trypsin) 또는 5μM PAR-2 활성 펩타이드(SLIGKV)를 처리하고 80초간 세포 내 Ca2+ 농도 변화를 측정하였다. 세포 내 Ca2+ 농도 변화 측정은 플렉스테이션3(FlexStation 3: Molecular Device, USA)를 이용하였다. 콩뿌리 추출물, 콩 추출물과 2U/ml 트립신(Trypsin) 또는 5μM PAR-2 활성 펩타이드(SLIGKV) 처리 후 80초간의 플렉스(flex)를 측정하여 얻어낸 값의 최소값과 최대값의 차를 구한 후, 그 값을 2U/ml 트립신 또는 5μM PAR-2 활성 펩타이드(SLIGKV) 처리 시의 최소값과 최대값의 차와 비교하여 칼슘 이온들의 세포 내 유입에 대한 억제율(%)을 하기 표 3에 나타내었다.After 10 minutes of reaction, the cells were treated with 2 U / ml trypsin or 5 μM PAR-2 active peptide (SLIGKV) and the change in intracellular Ca 2+ concentration was measured for 80 seconds. Measurement of intracellular Ca 2+ concentration was performed using FlexStation 3 (Molecular Device, USA). The difference between the minimum value and the maximum value obtained by measuring the flex for 80 seconds after treatment with soybean root extract and soybean extract and 2 U / ml trypsin or 5 μM PAR-2 active peptide (SLIGKV) (%) Against intracellular influx of calcium ions is shown in Table 3 below, by comparing the value with the difference between the minimum value and the maximum value when treating 2 U / ml trypsin or 5 μM PAR-2 active peptide (SLIGKV).
농도Test substance
density
상기 표 3에서 알 수 있듯이, 트립신 또는 PAR-2 활성 펩타이드(SLIGKV)에 의한 세포 내 칼슘 이온들의 유입이 콩뿌리 추출물의 처리에 따라 감소되며, 콩뿌리 추출물의 농도를 높여줌에 따라 세포 내 칼슘 이온들의 유입이 현저하게 감소됨을 확인할 수 있었다. 또한 콩 추출물과 비교 하여도 현저히 높은 칼슘 이온 유입 억제 효능을 확인 할 수 있다.따라서, 본 발명의 콩뿌리 추출물을 함유하는 피부 외용제 조성물은 가려움을 유발시키는 PAR-2 활성을 효과적으로 억제함으로써 우수한 항소양 효과를 제공할 수 있다.As shown in Table 3, the influx of intracellular calcium ions by trypsin or PAR-2 activating peptide (SLIGKV) is decreased by the treatment of soybean root extract, and as the concentration of soybean root extract is increased, intracellular calcium ions In the case of the present invention. Therefore, the composition for external application for skin containing the soybean root extract of the present invention effectively inhibits the itching-inducing PAR-2 activity, and thus the superior appealing amount Effect can be provided.
[시험예 3] 여드름균에 대한 항균력 시험[Test Example 3] Test for antimicrobial activity against acne bacteria
하기 표 4에 나타낸 성분 및 함량(중량%)에 따라 제형예 1 및 비교제형예 1~3를 제조하였다. 구체적으로 설명하면, 제형예 1은 콩뿌리 추출물을 배합시킨 것이고, 비교제형예 1은 여드름 피부 개선의 유효성분을 전혀 포함시키지 않은 것이며, 비교제형예 2는 항균력에 대한 기준으로 삼을 표준물질로서, 여드름 치료제로 많이 사용하는 에리스롬마이신(erythromycin)을 함유시킨 것이다. 비교제형예 3은 콩 추출물을 배합시킨 제형이다.Formulation Example 1 and Comparative Formulation Examples 1 to 3 were prepared according to the ingredients and the contents (% by weight) shown in Table 4 below. Specifically, Formulation Example 1 was prepared by adding soybean root extract, Comparative Formulation Example 1 contained no active ingredient for acne skin improvement, Comparative Formulation Example 2 was used as a standard for antibacterial activity, , Erythromycin (erythromycin), which is widely used as an acne remedy. Comparative Formulation Example 3 is a formulation in which a soybean extract is blended.
제형예 1 및 비교제형예 1~3의 제조 방법은 다음과 같다. 하기 표 4의 A상의 성분들을 완전 용해시키고 별도의 용해조에서 B상의 성분들을 완전 용해시킨 다음, B상을 A상에 첨가하여 혼합 가용화 시켰다. 여기에 C상의 성분들을 표 4에 기재된 배합비율에 따라 첨가하여 혼합 균일화시킨 다음 여과시켜 본 조성물들을 제조하였다.The manufacturing method of Formulation Example 1 and Comparative Formulation Examples 1 to 3 is as follows. The components of phase A in Table 4 were completely dissolved, the components of phase B were completely dissolved in a separate melting tank, and the phase B was added to the phase A to be mixed and solubilized. The components of the C phase were added thereto in accordance with the mixing ratios shown in Table 4, followed by mixing and homogenization, and then filtration to prepare the compositions.
(hydrogenated castor oil)PEG-60 hardened castor oil
(hydrogenated castor oil)
제형예 1 및 비교제형예 1~3의 조성으로 제조된 각각의 화장료 조성물을 가지고 여드름 원인 균주인 프로피오니박테리움 아크네스(ATCC 6919: 배지-BHI 브로스(broth))에 대하여 항균력을 시험하였다.여드름균에 대한 항균력 시험 방법은 다음과 같았다.Each of the cosmetic compositions prepared in the formulations of Formulation Example 1 and Comparative Formulations 1 to 3 was tested for antibacterial activity against Propionibacterium acnes (ATCC 6919: medium-BHI broth), which is a causative agent of acne. The test method for the antimicrobial activity against acne bacteria was as follows.
(1) 시험 균액 준비(1) Preparation of test strain
프로피오니박테리움 아크네스는 BHI 브로스에 접종하여 혐기 배양한 배양액을 사용하였다.Propionibacterium acnes were cultured in an anaerobic culture inoculated on BHI broth.
(2) 희석 용액 준비(2) Dilution solution preparation
BHI 브로스(pH 6.8) 또는 LB 브로스(pH 4.5) 15ml에 상기 시험 균액을 0.15ml 첨가하여 잘 혼합한 것을 희석용액으로 사용하였다.0.15 ml of the above test solution was added to 15 ml of BHI broth (pH 6.8) or LB broth (pH 4.5), and the mixture was used as a dilute solution.
(3) 시료 준비(3) Preparation of sample
제형예 1 및 비교제형예 1~3로부터 제조된 화장료 조성물 원액 그대로를 시료로 사용하였다.The undiluted solution of the cosmetic composition prepared from Formulation Example 1 and Comparative Formulation Examples 1 to 3 was used as a sample.
(4) 항균력 시험(4) Antimicrobial activity test
1) 96웰의 세포 배양관(96 well plate) 1번 행에 출발 농도에 맞도록 시료를 넣고 희석용액으로 총량을 200μl씩을 넣는다.1) In a 96-well 96-well plate, place the sample in line 1 and add 200 μl of diluted solution.
2) 1번 행의 혼합액을 잘 섞어준 다음 100μl를 취하여 2번 행에 넣고 잘 섞어준 다음, 다시 100μl를 취하여 3번 행에 넣는 방식으로 이중 희석(double dilution)을 행한다.2) Thoroughly mix the mixture of line 1, and then take 100 μl of the mixture, place it in the second row, mix well, and then repeat the double dilution by adding 100 μl to the third row.
3) 32℃에서 24시간 및 48시간 정치 배양한 후 현탁된 정도로 균의 증식 유무를 판단하여 균의 증식이 없는 최소농도를 MIC(최소저지농도; Minimum Inhibitory Concentration) 값으로 결정한다. 만약 혼합액이 불투명하여 균의 증식 유무를 판단하기 어려우면 현미경 관찰을 통하여 확인한다.3) After culturing the cells at 32 ° C for 24 hours and 48 hours, determine whether the bacteria are proliferating to the extent of suspension, and determine the minimum concentration without bacterial growth as the MIC (Minimum Inhibitory Concentration) value. If the mixture is opaque and it is difficult to judge the growth of the microorganism, check with a microscope.
여드름균에 대한 항균력 시험 결과를 하기 표 5에 나타내었다. MIC는 제형에 함유된 유효성분의 농도로 환산하여 표기하였다.The results of the antimicrobial activity test against acne bacteria are shown in Table 5 below. The MIC was expressed in terms of the concentration of the active ingredient contained in the formulation.
MIC에서 ppm 농도가 작을수록 여드름균에 대한 항균력에 대하여 유효한 물질이라고 할 수 있는데, 제형예 1의 경우 공지의 여드름 치료제인 에리스롬마이신을 사용한 비교제형예 2보다 ppm 농도가 현저하게 작게 나와 콩뿌리 추출물을 함유하는 조성물은 시험균에 대하여 훨씬 우수한 항균력을 가짐을 확인할 수 있다. 또한 콩 추출물을 함유한 비교제형예 3에 비해 서도 현저히 높은 항균 효과를 확인 할 수 있다. The lower the ppm concentration in the MIC, the more effective the antimicrobial activity against acne bacteria. In the case of Formulation 1, the ppm concentration is significantly smaller than that of Comparative Formulation Example 2 using erythromycin, which is a known acne treatment agent, It can be confirmed that the composition containing the extract has much better antibacterial activity against the test bacteria. In addition, the antibacterial effect remarkably higher than that of Comparative Formulation Example 3 containing soybean extract can be confirmed.
[시험예 4] 모공축소 효과[Test Example 4] Pore reduction effect
본 발명의 조성물에 의한 조성물을 화장료로 사용하기 위하여, 콩뿌리 추출물과 콩 추출물을 함유하는 조성물을 하기 표 6에 명시된 조성으로 크림을 제조하였다.In order to use the composition of the present invention as a cosmetic, a composition containing soybean root extract and soybean extract was prepared in the composition shown in Table 6 below.
베헤닐 알코올 & 소디움 스테아로일 락틸에이트Polyglyceryl-10 < / RTI > pentastearate &
Behenyl alcohol and sodium stearoyl lactylate
1. 콜라겐 생합성 촉진을 통한 모공 축소 효과1. Collagen biosynthesis promotes pore reduction effect
본 발명에 의한 콩뿌리 추출물의 콜라겐 생합성 촉진 효과를 TGF-β와 비교하여 측정하였다. 먼저, 섬유아세포(fibroblast)를 24 공(well)에 1 공 당 105개씩 파종(seeding)하여 90% 정도 자랄 때까지 배양하였다. 이를 24시간 동안 무혈청 DMEM 배지로 배양한 후 무혈청 배지에 녹인 본 발명의 콩뿌리 추출물, 콩 추출물과 TGF-β를 각각 10㎎/㎖씩 처리하고 CO2 배양기에서 24시간 동안 배양하였다. 이들의 상층액을 떠내어 프로콜라겐 형(I) ELISA 키트(procollagen type(I))를 이용하여 프로콜라겐 (procollagen)의 증감여부를 보았다. 그 결과를 하기 표 7에 나타내었으며, 콜라겐의 합성능은 비처리군을 100으로 하여 대비하였다.The collagen biosynthesis promotion effect of the soybean root extract according to the present invention was measured in comparison with TGF-β. First, fibroblasts were seeded at 10 5 per well in 24 wells and cultured until they grew to about 90%. The cells were cultured for 24 hours in a serum-free DMEM medium. Then, the soybean root extract, soybean extract and TGF-β of the present invention dissolved in serum-free medium were treated with 10 mg / ml each and cultured in a CO 2 incubator for 24 hours. The supernatant was removed and the procolagen (I) ELISA kit (procollagen type (I)) was used to determine whether procollagen was increased or decreased. The results are shown in Table 7 below, and the combined performance of the collagen was set to 100 in the non-treatment group.
상기 표 7의 결과에서, 본 발명에 의한 콩뿌리 추출물은 양성대조군인 TGF-β 과 비슷한 콜라겐 합성능을 나타내는 것을 확인할 수 있었다. 또한 콩 추출물에 비해서도 현저한 콜라겐 합성 효과를 확인 할 수 있다. 따라서, 본 발명에 의한 콩뿌리 추출물이 모공 주변의 콜라겐 생성량을 증가시켜 넓어진 모공을 축소시킬 수 있음을 확인하였다.From the results shown in Table 7, it was confirmed that the soybean root extract according to the present invention exhibited collagen aggregation performance similar to that of TGF-β, which is a positive control group. In addition, remarkable collagen synthesis effect can be confirmed as compared with soybean extract. Therefore, it was confirmed that the soybean root extract according to the present invention can increase collagen production around the pore, thereby reducing the enlarged pores.
2. 모공 축소 효과2. Pore reduction effect
제형예 2 및 비교제형예 4~5의 모공 축소 효과를 알아보기 위하여 다음과 같이 평가하였다. 모공 크기가 넓은 피험자 남녀 30명을 선정하여 10명씩 3개 군으로 나누고 각 군별로 얼굴에 제형예 2 및 비교제형예 3의 영양크림을 4주간 매일 바르게 하였다. 모공 축소의 효과에 대한 판정은 실험 전과 4주 후 사진을 찍어서 전문가들의 육안 평가로 이루어졌다. 그 결과는 하기 표 8에서 나타내었다. (평가 등급: 0 - 전혀 축소 되지 않았다; 5 - 매우 축소되었다)In order to examine the pore reduction effect of Formulation Example 2 and Comparative Formulation Examples 4 to 5, the following evaluation was made. Thirty male and female subjects with large pore sizes were selected and divided into three groups of 10 persons. The nutritional creams of Formulation Example 2 and Comparative Formulation Example 3 were applied to the face each day for 4 weeks. The evaluation of the effectiveness of the pore reduction was made by a visual evaluation of experts by taking pictures before and after the experiment. The results are shown in Table 8 below. (Rating scale: 0 - not reduced at all; 5 - very scaled down)
상기 표 8의 결과로부터, 비교제형예 4~5은 모공 축소 효과가 거의 없지만, 제형예 2의 경우에는 육안으로 확인 가능할 정도의 모공 축소 효과를 나타내어 본 발명에 의한 콩뿌리 추출물은 모공의 크기를 감소시키는 효과가 우수함을 알 수 있었다.이하, 본 발명에 따른 조성물의 제형 예를 설명하나, 약학 조성물 및 화장료 조성물은 여러 가지 제형으로 응용 가능하며, 이는 본 발명을 한정하고자 함이 아닌 단지 구체적으로 설명하고자 함이다.From the results of the above Table 8, Comparative Formulation Examples 4 and 5 have almost no effect of reducing pores. However, Formulation Example 2 shows a pore-shrinking effect to a degree that can be visually confirmed, and the soybean root extract according to the present invention has a pore size The pharmaceutical composition and the cosmetic composition according to the present invention can be applied to various formulations. However, the present invention is not limited to the specific formulation I want to explain.
[제제예 1] 연질캅셀제[Formulation Example 1] Soft capsule
콩뿌리 추출물 150 mg, 팜유 2 mg, 팜경화유 8 mg, 황납 4 mg 및 레시틴 6 mg을 혼합하고, 통상의 방법에 따라 1 캡슐당 400 mg씩 충진하여 연질캅셀을 제조하였다.A soft capsule was prepared by mixing 150 mg of soybean root extract, 2 mg of palm oil, 8 mg of palm kernel oil, 4 mg of yellow radish and 4 mg of lecithin and 400 mg per capsule according to a conventional method.
[제제예 2] 정제[Formulation Example 2] Tablets
콩뿌리 추출물 150 mg, 포도당 100 mg, 홍삼추출물 50 mg, 전분 96 mg 및 마그네슘 스테아레이트 4 mg을 혼합하고 30% 에탄올을 40 mg 첨가하여 과립을 형성한 후, 60℃에서 건조하고 타정기를 이용하여 정제로 타정하였다.The granules were prepared by mixing 150 mg of soybean root extract, 100 mg of glucose, 50 mg of red ginseng, 96 mg of starch and 4 mg of magnesium stearate and 40 mg of 30% ethanol, followed by drying at 60 ° C., Tablets were tableted.
[제제예 3] 과립제[Formulation Example 3] Granules
콩뿌리 추출물 150 mg, 포도당 100 mg, 홍삼추출물 50 mg 및 전분 600 mg을 혼합하고 30% 에탄올을 100 mg 첨가하여 과립을 형성한 후, 60℃에서 건조하여 과립을 형성한 다음 포에 충진하였다. 내용물의 최종 중량은 1 g으로 하였다.The granules were prepared by mixing 150 mg of soybean root extract, 100 mg of glucose, 50 mg of red ginseng extract and 600 mg of starch and 100 mg of 30% ethanol, and dried at 60 ° C. to form granules. The final weight of the contents was 1 g.
[제제예 4] 드링크제[Formulation Example 4] Drinking agent
콩뿌리 추출물 150 mg, 포도당 10 g, 홍삼추출물 50 mg, 구연산 2 g 및 정제수 187.8 g을 혼합하고 병에 충진하였다. 내용물의 최종 용량은 200 ml로 하였다.150 mg of soybean root extract, 10 g of glucose, 50 mg of red ginseng extract, 2 g of citric acid and 187.8 g of purified water were mixed and filled in a bottle. The final volume of the contents was adjusted to 200 ml.
[제제예 5] 건강 식품의 제조[Formulation Example 5] Preparation of health food
콩뿌리 추출물 .............................. 1000 ㎎ Soybean root extract .............................. 1000 mg
비타민 혼합물 Vitamin mixture
비타민 A 아세테이트.......................70 ㎍ Vitamin A Acetate ....................... 70 ㎍
비타민 E ............................................ 1.0 ㎎ Vitamin E ............................................ 1.0 mg
비타민 B1........................................... 0.13 ㎎ Vitamin B1 ........................................... 0.13 mg
비타민 B2 .......................................... 0.15 ㎎ Vitamin B2 .......................................... 0.15 mg
비타민 B6........................................... 0.5 ㎎ Vitamin B6 ........................................... 0.5 mg
비타민 B12......................................... 0.2 ㎍ Vitamin B12 .............................. 0.2 g
비타민 C............................................. 10 ㎎ Vitamin C ............................................. 10 mg
비오틴.................................................. 10 ㎍ Biotin ................................................. 10 [mu] g
니코틴산아미드.................................. 1.7 ㎎ Nicotinic acid amide .................................. 1.7 mg
엽산...................................................... 50 ㎍ Folic acid ................................................. ..... 50 μg
판토텐산 칼슘.................................... 0.5 ㎎ Calcium pantothenate .................................... 0.5 mg
무기질 혼합물 Mineral mixture
황산제1철.......................................... 1.75 ㎎ Ferrous sulfate .......................................... 1.75 mg
산화아연.............................................. 0.82 ㎎ Zinc oxide ............................................ 0.82 mg
탄산마그네슘...................................... 25.3 ㎎ Magnesium carbonate ...................................... 25.3 mg
제1인산칼륨.......................................... 15 ㎎ Potassium Phosphate ......................................... 15 mg
제2인산칼슘.......................................... 55 ㎎ Secondary calcium phosphate ...................................... 55 mg
구연산칼륨............................................ 90 ㎎ Potassium citrate ............................................ 90 mg
탄산칼슘.............................................. 100 ㎎ Calcium carbonate .............................................. 100 mg
염화마그네슘..................................... 24.8 ㎎ Magnesium chloride ..................................... 24.8 mg
상기의 비타민 및 미네랄 혼합물의 조성비는 비교적 건강식품에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 그 배합비를 임의로 변형 실시하여도 무방하며, 통상의 건강식품 제조방법에 따라 상기의 성분을 혼합한 다음, 과립을 제조하고, 통상의 방법에 따라 건강식품 조성물 제조에 사용할 수 있다.Although the composition ratio of the above-mentioned vitamin and mineral mixture is comparatively mixed with a composition suitable for health food as a preferred embodiment, the compounding ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional method for producing healthy foods , Granules can be prepared and used in the manufacture of health food compositions according to conventional methods.
[제제예 6] 건강 음료의 제조 [Formulation Example 6] Preparation of health drink
콩뿌리 추출물............................ 1000 ㎎ Soybean root extract ............................ 1000 mg
구연산..................................................... 1000 ㎎ Citric acid ................................................. ... 1000 mg
올리고당..................................................... 100 g oligosaccharide................................................. .... 100 g
매실농축액..................................................... 2 g Plum concentrate ................................................ ..... 2 g
타우린............................................................ 1 g Taurine ................................................. ........... 1 g
정제수를 가하여 전체......................... 900 ㎖ Purified water was added to the mixture to complete 900 ml
통상의 건강음료 제조방법에 따라 상기의 성분을 혼합한 다음, 약 1시간 동안 85℃에서 교반 가열한 후, 만들어진 용액을 여과하여 멸균된 2ℓ용기에 취득하여 밀봉 멸균한 뒤 냉장 보관한 다음 본 발명의 건강음료 조성물 제조에 사용한다.The above components were mixed according to a conventional health drink manufacturing method, and the mixture was heated for about 1 hour at 85 DEG C with stirring, and the solution thus prepared was filtered to obtain a sterilized 2-liter container, which was sealed and sterilized, ≪ / RTI >
상기 조성비는 비교적 기호음료에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만 수요계층이나, 수요국가, 사용 용도 등 지역적, 민족적 기호도에 따라서 그 배합비율을 임의로 변형 실시하여도 무방하다. 본 발명이 속한 기술 분야에서 통상의 지식을 가진 자라면 상기 내용을 바탕으로 본 발명의 범주 내에서 다양한 응용 및 변형을 행하는 것이 가능할 것이다. Although the composition ratio is relatively mixed with a component suitable for a favorite drink, it is also possible to arbitrarily modify the blending ratio according to the regional or national preference such as the demand level, the demanding country, the use purpose, and the like. It will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention as defined by the appended claims.
[제형예 3] 유연화장수(스킨로션)[Formulation Example 3] Softening lotion (skin lotion)
[제형예 4] 영양화장수(밀크로션)[Formulation Example 4] Nutritional lotion (milk lotion)
[제형예 5] 영양크림[Formulation Example 5] Nourishing cream
[제형예 6] 마사지 크림[Formulation Example 6] Massage cream
[제형예 7] 팩[Formulation Example 7] Pack
[제형예 8] 연고[Formulation Example 8] ointment
이상으로 본 발명 내용의 특정한 부분을 상세히 기술하였는 바, 당업계의 통상의 지식을 가진 자에게 있어서 이러한 구체적 기술은 단지 바람직한 실시태양일 뿐이며, 이에 의해 본 발명의 범위가 제한되는 것이 아닌 점은 명백할 것이다. 따라서, 본 발명의 실질적인 범위는 첨부된 청구항들과 그것들의 등가물에 의하여 정의된다고 할 것이다.While the present invention has been particularly shown and described with reference to specific embodiments thereof, those skilled in the art will readily appreciate that many modifications are possible in the exemplary embodiments without materially departing from the novel teachings and advantages of this invention. something to do. Accordingly, the actual scope of the present invention will be defined by the appended claims and their equivalents.
Claims (8)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020180142685A KR101997033B1 (en) | 2018-11-19 | 2018-11-19 | Composition for antiinflammation containing extract of soybean root |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020180142685A KR101997033B1 (en) | 2018-11-19 | 2018-11-19 | Composition for antiinflammation containing extract of soybean root |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020120083708A Division KR102033448B1 (en) | 2012-07-31 | 2012-07-31 | Composition for antiinflammation containing extract of soybean root |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20180127625A true KR20180127625A (en) | 2018-11-29 |
| KR101997033B1 KR101997033B1 (en) | 2019-07-08 |
Family
ID=64566951
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020180142685A KR101997033B1 (en) | 2018-11-19 | 2018-11-19 | Composition for antiinflammation containing extract of soybean root |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101997033B1 (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR19980077876A (en) | 1997-04-23 | 1998-11-16 | 서영필 | Cosmetic composition containing honey extract or soy extract |
| KR20110110052A (en) * | 2010-03-31 | 2011-10-06 | (주)아모레퍼시픽 | Composition for beauty of skin containing coumestrol or soy bean extract with coumestrol |
-
2018
- 2018-11-19 KR KR1020180142685A patent/KR101997033B1/en active IP Right Grant
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR19980077876A (en) | 1997-04-23 | 1998-11-16 | 서영필 | Cosmetic composition containing honey extract or soy extract |
| KR20110110052A (en) * | 2010-03-31 | 2011-10-06 | (주)아모레퍼시픽 | Composition for beauty of skin containing coumestrol or soy bean extract with coumestrol |
Also Published As
| Publication number | Publication date |
|---|---|
| KR101997033B1 (en) | 2019-07-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20070079497A (en) | External composition for improvement of skin containing herbal extracts | |
| KR20180106155A (en) | Whitening and moisturizing functional composition comprising a fermentation material of a natural mixture | |
| KR102016640B1 (en) | Composition containing extract using process of herbal medicine | |
| KR102299276B1 (en) | Compositions containing oils of glycine gracilis | |
| KR20130120597A (en) | Composition for anti-inflammatory containing soybean extract of fermentation by flower | |
| KR102076001B1 (en) | Composition for antiinflammation containing extract of soybean leaf | |
| KR101997033B1 (en) | Composition for antiinflammation containing extract of soybean root | |
| KR101571131B1 (en) | Composition for anti-allergy containing paeonia anomala extract | |
| KR101973640B1 (en) | Composition comprising extract of grifola frondosa fruit body | |
| KR102238329B1 (en) | Skin funtional composition containing fermented natural product complex by lactic acid | |
| KR20150057331A (en) | Composition for improving skin condition comprising extract of korean fir | |
| KR102014962B1 (en) | Composition for antiinflammation containing extract of soybean pod | |
| KR102033448B1 (en) | Composition for antiinflammation containing extract of soybean root | |
| KR102123588B1 (en) | Antioxidation and whitening active composition containing complex seaweed fermented extract | |
| KR102014965B1 (en) | Composition containing extract using process of herbal medicine | |
| KR102014961B1 (en) | Composition for anti oxidation containing extract of soybean pod | |
| KR102030680B1 (en) | Composition comprising Panax ginseng polysaccharide and Green tea polysaccharide for improving skin trouble | |
| KR20200092669A (en) | Skin functional composition containing fermented artemisia capillaris | |
| KR101940053B1 (en) | Composition containing extract using process of herbal medicine | |
| KR102027453B1 (en) | Composition containing extract using process of herbal medicine | |
| KR101436923B1 (en) | Antibacterial oral composition containg cirsium sp exctract | |
| KR102014960B1 (en) | Composition for anti oxidation containing extract of soybean root | |
| KR101457996B1 (en) | Antibacterial composition containg staphylea sp.exctract | |
| KR102159128B1 (en) | Composition containing extract of mixture of kajime and red shell | |
| KR102022898B1 (en) | Composition containing extract using process of herbal medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A107 | Divisional application of patent | ||
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |